<https://helda.helsinki.fi>

A point-of-care test of active matrix metalloproteinase-8 predicts triggering receptor expressed on myeloid cells-1 levels in saliva

Räisänen, Ismo T.

2020-01

Räisänen , I T , Heikkinen , A M , Pakbaznejad Esmaeili , E , Tervahartiala , T , Pajukanta , R , Silbereisen , A , Bostanci , N & Sorsa , T 2020 , ' A point-of-care test of active matrix metalloproteinase-8 predicts triggering receptor expressed on myeloid cells-1 levels in saliva ' , Journal of Periodontology , vol. 91 , no. 1 , pp. 102-109 . <https://doi.org/10.1002/JPER.19-0132>

<http://hdl.handle.net/10138/312973>

<https://doi.org/10.1002/JPER.19-0132>

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

A Point-Of-Care Test of Active Matrix Metalloproteinase-8 (Amp-8) Predicts Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) Levels in Saliva

Ismo T. Räisänen^{*}, Anna Maria Heikkinen^{*}, Elmira Pakbaznejad Esmaeili^{*}, Taina Tervahartiala^{*}, Riitta Pajukanta^{*}, Angelika Silbereisen[†], Nagihan Bostanci[†] and Timo Sorsa^{*,†}

^{*} Department of Oral and Maxillofacial Diseases, Head and Neck Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

[†] Section of Periodontology and Dental Prevention, Division of Oral Diseases, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden.

Correspondence

Ismo T. Räisänen

Department of Oral and Maxillofacial Diseases, University of Helsinki

P.O. Box 41 (Mannerheimintie 172) FI-00014, Helsinki, Finland.

Email: ismo.raisanen@helsinki.fi

2,891 Words, 3 Figures, 1 Table, and 50 References

Short Running Title: POC test of aMMP-8 predicts TREM-1 levels in saliva

One-Sentence Summary: The present study validated usability of aMMP-8 point-of-care test for predicting pro-inflammatory profile in saliva of adolescents.

ABSTRACT

Background: This cross-sectional study aims to investigate if a point-of-care (PoC) test of active matrix metalloproteinase-8 (aMMP-8) predicts levels of inflammation amplifier TREM-1 and its putative ligand the neutrophil peptidoglycan recognition protein 1 (PGLYRP1) in saliva.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/JPER.19-0132](#).

This article is protected by copyright. All rights reserved.

Methods: Forty-seven adolescents, aged 15-17, were tested with aMMP-8 PoC test, which was followed by a full-mouth clinical examination of the assessment of periodontal, mucosal and oral health. TREM-1 and PGLYRP1 levels were analyzed by ELISA. The IFMA assay specific for aMMP-8 was used as the reference method.

Results: 14 saliva samples out of total of 47 samples showed positivity for aMMP-8 PoC test. Both the TREM-1 and the aMMP-8 (IFMA) levels were significantly elevated among the aMMP-8 PoC test positives compared to the PoC test negatives ($P < 0.05$). Moreover, aMMP-8 levels assessed by IFMA showed a strong positive correlation with TREM-1 levels in saliva ($r = 0.777$, $P < 0.001$). The number of periodontal pockets with ≥ 4 mm was significantly lower among the adolescents with a negative aMMP-8 PoC test result and TREM-1 levels below 75 pg/mL ($P < 0.05$). In contrast, adolescents with a positive aMMP-8 PoC test result (i.e. elevated aMMP-8 levels) together with elevated TREM-1 levels had significantly higher number of periodontal pockets with ≥ 4 mm ($P < 0.001$).

Conclusions: The present study validated usability of aMMP-8 PoC test for predicting “pro-inflammatory” salivary profile and periodontal health status in adolescents.

KEYWORDS: Biomarkers; Periodontitis; Triggering Receptor Expressed on Myeloid Cells-1; Matrix Metalloproteinases; Point-of-Care Testing

1 INTRODUCTION

Periodontitis is a common oral inflammatory disorder induced by impaired host response to periodontal pathogens leading to a loss of connective tissue and bone support.¹ Severe periodontitis, which eventually results in tooth loss, has prevalence of 5-20% in most adult populations worldwide.¹ Children and adolescents can also suffer from periodontal attachment loss.² According to Heikkinen et al. (2008)³ prevalence of initial or early periodontitis (called subclinical periodontitis), where the clear clinical and x-ray manifestations of deterioration of periodontal health are yet lacking, was 10-15% among 15-16-year-olds of Kotka, Finland.

The triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell surface receptor of the immunoglobulin superfamily expressed on monocytes, macrophages and neutrophils during inflammatory and infectious processes.⁴ Yet, TREM-1 expression is not limited to myeloid cells as TREM family members have been detected also in epithelial cells e.g. in gingiva.⁵ TREM-1 plays an important signaling role as it regulates the magnitude of the host's inflammatory response to bacteria, viruses and fungi.⁴⁻⁸ Activation of TREM-1 leads to a cascade of intracellular signaling events resulting in inflammatory effects, such as enhanced cytokine production, activation and degranulation of neutrophils and phagocytosis.⁹ In addition to the membrane-bound form of TREM-1, there also exists a soluble form of TREM-1.¹⁰ Its concentration in saliva, gingival crevicular fluid

(GCF) and serum has been shown to be risen at the presence of periodontitis, proposing it to be a potential biomarker for periodontitis in adults.¹¹⁻¹⁴

More recently, the neutrophil peptidoglycan recognition protein 1 (PGLYRP1) has been identified as a functional ligand for TREM-1 and capable of inducing TREM-1 activation.¹⁵ PGLYRP1 is known as an antibacterial protein against Gram-positive and Gram-negative bacteria.¹⁶ Other ligands for TREM-1 include high-mobility group box 1 protein (HMGB1), heat shock protein 70 (hsp 70), a ligand expressed on platelets, extracellular actin, as well as bacterial peptidoglycans and lipopolysaccharides.¹⁷⁻²¹

There are studies that have identified proteolytic matrix metalloproteinases (MMPs) to be responsible for processing membrane bound TREM-1 to its soluble form.^{22,23} Activated MMP-8 (aMMP-8) is already known as one of the most validated periodontitis biomarkers.^{24,25} Several studies have reported that the progression of periodontitis is reflected as an excessive elevation and activation of total MMP-8 and aMMP-8 in oral fluids.²⁴⁻³⁵ This stage can be measured using a point-of-care (PoC) lateral flow collagenase-2 (aMMP-8) immunotest.^{24,29,30,36-46} Moreover, previously there have been found a moderate positive association / correlation between MMP-8/PGLYRP1 axis and TREM-1 levels among adults,¹⁴ but to the best of author's knowledge, this association hasn't been studied among adolescent subjects before. A non-invasive, quick, easy to use and inexpensive aMMP-8 PoC test, which is currently available also as a quantitative point-of-care aMMP-8 test, may be also a potential tool for point of care detection of salivary TREM-1 levels and as such for detection of periodontal and systemic inflammation. Thus, our aim was to study whether the concentrations of TREM-1 and its natural ligand PGLYRP1 could be linked to the aMMP-8 PoC/ chairside test result. We used the aMMP-8 IFMA levels as a reference method. In this regard, our hypothesis was that the salivary concentrations of TREM-1 and PGLYRP1 has a positive association with the aMMP-8 PoC test result and the aMMP-8 (IFMA) levels. Another hypothesis was that the aMMP-8 PoC test has a positive association with the number of ≥ 4 mm deep periodontal pockets.

MATERIALS AND METHODS

1.1 Study cohort

Forty-seven patients of a birth cohort of 15- to 17-year-olds participated in this cross-sectional study, which was carried out in Kotka Health Center, Kotka, Eastern Finland in 2014 and 2015. One participant had been excluded due to gender check.^{29,30} The study was approved by the Ethical Committee of the Helsinki and Uusimaa Hospital District (Diary number 260/13/03/00/13) and was conducted according to the principles of the Declaration of Helsinki of 1975, as revised in 2000.⁴⁷ All participants (their parents/guardians) gave their written informed consent and were examined for a full-mouth clinical examination of periodontal, mucosal and oral health as well as health habits as described earlier by Heikkinen et al.^{29,30} In detail, periodontal probing depth (≥ 4 mm), bleeding on probing (BOP), root calculus (RC) and visible plaque index (VPI) were recorded at four sites per tooth. RC and VPI were recorded from index teeth.^{29,30} Additionally, patient's smoking history and oral hygiene habits were included in the dental health care system electronic records.

1.2 aMMP-8 PoC testing

Saliva samples were collected and the aMMP-8 PoC test was performed as described earlier.^{29,30,45} The same person (AMH) performed all the clinical measurements and the collection of saliva samples. Briefly, aMMP-8 PoC test result was read in 5-7 minutes as a color change resulting from immunoreactions after placing maximum of 4 drops of mouthrinse in the lateral flow immunoassay system by a trained assistant. One single blue line on the test device indicated a negative test result, and no risk for active periodontal tissue destruction and periodontitis; while two blue lines indicated a positive test result, and an increased risk for active periodontal tissue destruction, and periodontitis.^{29,30,46} An independent consulting company has defined and validated the cut-off point (20 ng/mL) of the aMMP-8 lateral flow point-of-care test before it was made available commercially.^{29,39,40,44,46} AMH was unaware of the aMMP-8 PoC test result when performing each clinical examination. Saliva samples were further analyzed for the presence and the levels of aMMP-8 (IFMA), TREM-1 and PGLYRP1 as described earlier by Nylund et al. (2018).¹⁴ Moreover, MMP-8 concentration was determined in accordance with the manufacturer's instructions by time-resolved immunofluorometric assay (IFMA, Medix Biochemica, Espoo, Finland) and lateral flow chairside/point-of-care immunoassay utilizing the same antibody.^{33,44-46,48} The inter-assay coefficient of variation (CV)% was 7.3% (n=28) and the detection limit was 0.08 µg/L for the assays in IFMA.^{33,36,48} Information regarding aMMP-8 (IFMA) was available for 47 patients, and TREM-1 and PGLYRP1 for 43 patients.

1.3 Statistical analysis

The relationship among the concentrations of TREM-1, PGLYRP1 and aMMP-8 was assessed by Spearman rank correlations (r_s). Normality assumption was assessed graphically with a histogram and a Q-Q plot, and numerically with the Shapiro-Wilk test. As a result, Mann-Whitney U test was used for testing the association between two groups of aMMP-8 Point-of-Care (PoC) test results ("positive", "negative") on aMMP-8, TREM-1 and PGLYRP1 levels. Kruskal Wallis test was used for testing differences in the number of ≥ 4 mm deep periodontal pockets, BOP, VPI, RC, and toothbrushing frequency per week between the groups classified by the aMMP-8 PoC test result, and TREM-1 levels together. Pairwise testing was adjusted with Bonferroni correction. Data analysis was performed, and figures plotted with statistical software.^{‡,§} A two-tailed *P* value less than 0.05 was considered as statistically significant.

2 RESULTS

2.1 Association between the aMMP-8 PoC test and aMMP-8 (IFMA), TREM-1, and PGLYRP1

Figure 1 illustrates the concentrations of aMMP-8 (IFMA), TREM-1 and PGLYRP1 according to aMMP-8 PoC test result. The median concentrations of aMMP-8 (IFMA) were 103.4 ng/mL (interquartile range [IQR], 56.7 to 211.8), TREM-1 145.2 pg/mL (IQR, 75.0 to 400.7) and PGLYRP1 6.1 ng/mL (IQR, 1.5 to 7.5) for the aMMP-8 PoC test negatives, and aMMP-8 (IFMA) 207.9 ng/mL (IQR, 131.0 to

[‡] SPSS Statistics, Version 25.0. Armonk, NY: IBM Corp

[§] R version 3.3.3: A language and environment for statistical computing. Vienna, Austria; 2017. Available at: <https://www.R-project.org/>.

235.4), TREM-1 407.6 pg/mL (IQR, 254.2 to 610.5) and PGLYRP1 6.9 ng/mL (IQR, 4.1 to 25.2) for the aMMP-8 PoC test positives (Figure 1). The concentrations of TREM-1 and aMMP-8 (IFMA) were statistically significantly elevated among the aMMP-8 PoC test positives compared to the test negatives ($P = 0.016$ and $P = 0.018$, respectively), whereas the difference in PGLYRP1 concentrations according to the aMMP-8 PoC test was not significant ($P = 0.242$).

2.2 Correlation analysis among aMMP-8 (IFMA), TREM-1 and PGLYRP1

There seemed to be a possible nonlinear relationship between TREM-1, PGLYRP1 and aMMP-8 (IFMA) concentrations, which was confirmed with Spearman's rank correlations (Figure 2). There was a strong positive correlation between TREM-1 and aMMP-8 (IFMA) concentrations ($r_s = 0.777$, $P < 0.001$), a moderate positive correlation between PGLYRP1 and aMMP-8 (IFMA) ($r_s = 0.526$, $P < 0.001$), and also a strong positive correlation between TREM-1 and PGLYRP1 ($r_s = 0.663$, $P < 0.001$) (Figure 2). Thus, the association between TREM-1 and the aMMP-8 PoC test result was verified with aMMP-8 (IFMA).

2.3 Association of TREM-1 and the aMMP-8 PoC test result with the number of ≥ 4 mm periodontal pockets

All of the adolescents with TREM-1 levels below 75 pg/mL ($n = 7$) were in safe zone having less than two ≥ 4 mm periodontal pockets (six adolescents with zero pockets and one adolescent with one pocket). In other words, a cut-off point of 75 pg/mL for TREM-1 resulted in sensitivity of 100%. However, the specificity of this cut-off point was only 31.8%. Figure 3 illustrates the number of at least two ≥ 4 mm periodontal pockets against aMMP-8 PoC test result clustered according to TREM-1. Median of the number of ≥ 4 mm periodontal pockets for the aMMP-8 PoC test negative adolescents was zero pockets (IQR, 0 to 0) for TREM-1 levels below 75 pg/mL ($n = 7$) and a one pocket (IQR, 0.0 to 2.0) for TREM-1 levels ≥ 75 pg/mL ($n = 22$), and for the aMMP-8 PoC test positive adolescents the median was eleven pockets (IQR, 5.8 to 15.3) for TREM-1 levels ≥ 75 pg/mL ($n = 14$). There were zero aMMP-8 PoC test positive adolescents with TREM-1 levels below 75 pg/mL. The number of ≥ 4 mm periodontal pockets was significantly lower among adolescents with an aMMP-8 PoC negative test result and TREM-1 levels below 75 pg/mL ($n = 7$) compared to adolescents with TREM-1 levels ≥ 75 pg/mL and a positive test ($n = 14$) result ($P < 0.001$). Further, adolescents with TREM-1 levels ≥ 75 pg/mL had significantly less ≥ 4 mm periodontal pockets when the aMMP-8 PoC test was negative compared to adolescents with a positive test ($P < 0.001$). But the difference in the number of ≥ 4 mm periodontal pockets was not significant (after Bonferroni correction) between adolescents classified by the TREM-1 cut-off of 75 pg/mL with a negative aMMP-8 PoC test result. There was not a statistically significant difference in the medians of BOP%, VPI%, RC% when classified by the aMMP-8 PoC test result, and TREM-1, and the cut-off point of 75 pg/mL ($p > 0.05$). However, the medians were markedly different for adolescents with a positive aMMP-8 PoC test result compared to adolescents with a negative test result (with either TREM-1 levels over or under the cut-off of 75 pg/mL) (Table 1).

2.4 Association of TREM-1 and the aMMP-8 PoC test result with oral hygiene habits

Finally, there was not a statistically significant difference in the medians of toothbrushing frequency per week when classified by the aMMP-8 PoC test result, and TREM-1, and the cut-off point of 75 pg/mL. (Table 1).

3 DISCUSSION

The present study is the first to investigate association between salivary concentrations of TREM-1, its natural ligand PGLYRP1 and the aMMP-8 PoC/ chairside test result among adolescents. Firstly, we found a significant association between the aMMP-8 PoC test result and the concentrations of TREM-1 and aMMP-8 (IFMA), but not between the aMMP-8 PoC test result and the concentration of PGLYRP1. Both the TREM-1 and the aMMP-8 (IFMA) levels were significantly higher among the aMMP-8 PoC test positives compared to the test negatives. Previous studies have found TREM-1 to be a potential risk indicator, in addition to periodontitis,¹² in different systemic inflammatory diseases such as in human sepsis and pneumonia.^{10,19,49,50} Further, Bostanci et al.¹² found a significant, moderate positive correlation between the salivary and serum concentrations of TREM-1 among systemically healthy periodontitis patients and their healthy controls. Thus, a non-invasive, quick, easy to use and inexpensive aMMP-8 PoC test that is currently available also as a quantitative point-of-care aMMP-8 test seems to be a potential tool for point of care detection of systemic TREM-1 levels and as such detection of systemic inflammatory diseases.

Secondly, there was also a strong positive correlation not only between the concentrations of TREM-1 and PGLYRP1, which probably results from PGLYRP1 being a functional ligand for TREM-1,¹⁵ but also between the concentrations of TREM-1 and aMMP-8 (IFMA). As the aMMP-8 (IFMA) levels increased this seemed to result in an exponential increase in the TREM-1 levels verifying the association between the aMMP-8 PoC test and the TREM-1 levels. Further, this suggests that there may be an aMMP-8 cleavage site in TREM-1 that allows aMMP-8 to process or shed membrane-bound TREM-1 to its soluble form. Although the approach in our study cannot directly reveal the cause–effect relationship between aMMP-8, TREM-1 and its soluble form, the result is in agreement with the findings of Gómez-Piña et al. (2007)²² that one or several of the proteolytic matrix metalloproteinases (MMP-1, MMP-2, MMP-3, MMP-8 and MMP-9) are responsible for this cleavage or shedding process of TREM-1. Also, a recent study identified a MMP-9 cleavage site in TREM-1 and that the increase of MMP-9 in bronchoalveolar lavage fluid reflects MMP-dependent release of TREM-1.²³ Moreover, we found also a moderate positive correlation between the aMMP-8 (IFMA) and PGLYRP1 levels, but the functional form of this relationship was not as clear and strong as between aMMP-8 (IFMA) and TREM-1 levels in our cohort of adolescents.

Finally, in the current literature, the role of soluble TREM-1 is still unclear, but previous studies have proposed it acting as a negative regulator of the TREM-1 pathway by competing from the TREM-1 signaling receptor with ligand(s).⁹ Thus, soluble TREM-1 may very well be regulating negatively the effect of aMMP-8 (and other MMPs) through preventing excessive activation of TREM-1 pathway. In the present study, we found that adolescents with low salivary TREM-1 levels had significantly fewer ≥ 4 mm periodontal pockets compared to adolescent with elevated TREM-1 levels (over a safe zone cut-off point of 75 pg/mL). However, this difference in TREM-1 levels was not significant anymore after adjusting for multigroup comparisons. Further, the number of ≥ 4 mm periodontal pockets were significantly higher among adolescents with a positive aMMP-8 PoC test result compared to adolescents with a negative test result regardless of TREM-1 levels (with cut-off point of 75 pg/mL). Even though low TREM-1 levels seemed to be associated with low amount of ≥ 4 mm periodontal (six adolescents with zero pockets and one adolescent with one pocket), there were also some adolescents who had no pockets while having elevated TREM-1 levels, and also a negative aMMP-8 PoC test result. This suggests that low levels of TREM-1 may be a good thing for periodontal health,

and therefore the true value of TREM-1 for periodontal diagnostics is mainly in assessing the absence of disease. The positive aMMP-8 PoC test result (indicating elevated aMMP-8 levels) seemed to have a greater association to periodontal health situation among adolescents than elevated TREM-1 levels. The subclinical periodontal destruction and the progression towards periodontitis seem to be more strongly associated with the positive aMMP-8 PoC test result, in other words, with elevated concentrations of aMMP-8.

This study has some limitations mainly related to the sample size. Our original aim was to get a whole birth cohort to participate in this study, but the inclusion of subjects for the aMMP-8 PoC testing (chairside) were based on approval of parents/guardians.^{29,30,45} Total of 47 adolescents' parents gave consent for the test, which may lead to limit the power of statistical tests to avoid the type two error. For example, the difference between PGLYRP1 levels according to the aMMP-8 PoC test result was not significant, even though there was a significant correlation between aMMP-8 (IFMA), TREM-1 and PGLYRP1 levels. However, the correlation between PGLYRP1 and aMMP-8 (IFMA) was not as clear and strong as between TREM-1 and aMMP-8 (IFMA). Still, we cannot exclude the possibility that the association between PGLYRP1 and the aMMP-8 PoC test exists. Also, there were some extreme TREM-1 and PGLYRP1 values, yet they were rare (7-10%), and their influence on the significance tests was minimized by using the non-parametric tests. Further, there were a few unexpectedly large values for aMMP-8 (IFMA) among adolescents with a negative aMMP-8 PoC test, when considering the plaque status, the number of deep periodontal pockets and the oral hygiene habits. Moreover, we found that the aMMP-8 PoC test had a significant association with BOP and VPI, while aMMP-8 (IFMA) did not (calculations not shown here). This suggests that there may have been some measurement errors related to aMMP-8 (IFMA) instead of false negative aMMP-8 PoC test results. Yet, it should be noted that although immunofluorometric assay and lateral immunoassay utilized the same antibody,^{33,44-46,48} they still are based on different kinds of technologies, which may also explain some of this phenomenon.

4 CONCLUSIONS

In summary, our study demonstrates the usability of aMMP-8 PoC/ chairside test in predicting pro-inflammatory profile in saliva of adolescents within only 5-7 minutes non-invasively and causing no discomfort to patient. There was also a significant strong positive correlation between the aMMP-8 (IFMA) and the TREM-1 levels. As the aMMP-8 (IFMA) levels increased the TREM-1 levels seemed to increase in exponential manner, suggesting an aMMP-8 cleavage site in TREM-1 that allows aMMP-8 to process or shed membrane-bound TREM-1 to soluble TREM-1. Moreover, the effect of increasing aMMP-8 levels assessed by the aMMP-8 PoC test seemed to outweigh the effect of increasing TREM-1 levels to the deterioration of periodontal health. Nevertheless, due to the cross-sectional nature of this study, the results are not definitive, and more research with other populations and larger sample sizes is needed to confirm our results.

ACKNOWLEDGEMENTS

This work was supported by grants from the University of Helsinki Research Foundation TYH 2016251, TYH 2017251, TYH 2018229, TYH 2019314, Y1014SL017, Y1014SL018, Y1014SULE1, Helsinki, Finland and the Karolinska Institutet, Stockholm, Sweden. Timo Sorsa is an inventor of US-patents 5652223, 5736341, 5866432, 6143476 and 20170023571A1.

CONFLICT OF INTEREST

The other authors report no conflicts of interest related to this study.

REFERENCES

1. Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global burden of severe periodontitis in 1990-2010: a systematic review and meta-regression. *J Dent Res*. 2014;93:1045-1053.
2. Albandar JM, Tinoco EM. Global epidemiology of periodontal diseases in children and young persons. *Periodontol 2000*. 2002;29:153-176.
3. Heikkinen AM, Pajukanta R, Pitkäniemi J, et al. The effect of smoking on periodontal health of 15- to 16-year-old adolescents. *J Periodontol*. 2008;79:2042-2047.
4. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. *J Immunol*. 2000;164:4991-4995.
5. Chen SS, Wang K, Zhao J, Wu WC, Wu YF, Zhao L. Increased expression of triggering receptor expressed on myeloid cells 1 and 2 in inflamed human gingiva. *J Periodontal Res*. 2017;52:512-521.
6. Bleharski JR, Kiessler V, Buonsanti C, et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. *J Immunol*. 2003;170:3812-3818.

7. Buckland KF, Ramaprakash H, Murray, LA, et al. Triggering receptor expressed on myeloid cells-1 (TREM-1) modulates immune responses to *Aspergillus fumigatus* during fungal asthma in mice. *Immunol Invest*. 2011;40:692-722.
8. Ivan FX, Rajapakse JC, Welsch RE, et al. Differential pulmonary transcriptomic profiles in murine lungs infected with low and highly virulent influenza H3N2 viruses reveal dysregulation of TREM1 signaling, cytokines, and chemokines. *Funct Integr Genomics*. 2012;12:105-117.
9. Varanat M, Haase EM, Kay JG, Scannapieco FA. Activation of the TREM-1 pathway in human monocytes by periodontal pathogens and oral commensal bacteria. *Mol Oral Microbiol*. 2017;32:275-287.
10. Gibot S, Cravoisy A. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. *Clin Med Res*. 2004;2:181-187.
11. Bisson C, Massin F, Lefevre PA, Thilly N, Miller N, Gibot S. Increased gingival crevicular fluid levels of soluble triggering receptor expressed on myeloid cells (sTREM) -1 in severe periodontitis. *J Clin Periodontol*. 2012;39:1141-1148.
12. Bostanci N, Öztürk VÖ, Emingil G, Belibasakis GN. Elevated oral and systemic levels of soluble triggering receptor expressed on myeloid cells-1 (TREM-1) in periodontitis. *J Dent Res*. 2013;92:161-165.
13. Belibasakis GN, Öztürk VÖ, Emingil G, Bostanci N. Soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) in gingival crevicular fluid: Association with clinical and microbiologic parameters. *J Periodontol*. 2014;85:204-210.
14. Nylund KM, Ruokonen H, Sorsa T, et al. Association of the salivary triggering receptor expressed on myeloid cells/its ligand peptidoglycan recognition protein 1 axis with oral inflammation in kidney disease. *J Periodontol*. 2018;89:117-129.
15. Read CB, Kuijper JL, Hjorth SA, et al. Cutting edge: identification of neutrophil PGLYRP1 as a ligand for TREM-1. *J Immunol*. 2015;194:1417-1421.
16. Dziarski R, Gupta D. Review: Mammalian peptidoglycan recognition proteins (PGRPs) in innate immunity. *Innate Immun*. 2010;16:168-174.
17. El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR. Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. *Immuno Lett*. 2007;111:36-44.
18. Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. *Cancer Res*. 2012;72:3977-3986.
19. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is critical mediator of septic shock. *Nature*. 2001;410:1103-1107.

20. Haselmayer P, Grosse-Hovest L, Von Landenberg P, Schild H, Radsak MP. TREM-1 ligand expression on platelets enhances neutrophil activation. *Blood*. 2007;110:1029-1035.
21. Fu L, Han L, Xie C, et al. Identification of extracellular actin as a ligand for triggering receptor expressed on myeloid cells-1 signaling. *Front Immunol*. 2017;8:917.
22. Gómez-Piña V, Soares-Schanoski A, Rodríguez-Rojas A, et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. *J Immunol*. 2007;179:4065-4073.
23. Weiss G, Lai C, Fife ME, et al. Reversal of TREM-1 ectodomain shedding and improved bacterial clearance by intranasal metalloproteinase inhibitors. *Mucosal Immunol*. 2017;10:1021–1030.
24. Sorsa T, Gürsoy UK, Nwhator S, et al. Analysis of matrix metalloproteinases, especially MMP-8, in gingival crevicular fluid, mouthrinse and saliva for monitoring periodontal diseases. *Periodontology 2000*. 2016;70:142-163.
25. Al-Majid A, Alassiri S, Rathnayake N, Tervahartiala T, Gieselmann DR, Sorsa T. Matrix metalloproteinase-8 as an inflammatory and prevention biomarker in periodontal and peri-implant diseases. *Int J Dent*. 2018;7891323. doi: 10.1155/2018/7891323
26. Lee W, Aitken S, Sodek J, McCulloch CA. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: role of active enzyme in human periodontitis. *J Periodontol Res*. 1995;30:23-33.
27. Romanelli R, Mancini S, Laschinger C, Overall CM, Sodek J, McCulloch CA. Activation of neutrophil collagenase in periodontitis. *Infect Immun*. 1999;67:2319-2326.
28. Mancini S, Romanelli R, Laschinger CA, et al. Assessment of a novel screening test for neutrophil collagenase activity in the diagnosis of periodontal diseases. *J Periodontol*. 1999;70:1292-1302.
29. Heikkinen AM, Nwhator SO, Rathnayake N, Mäntylä P, Vatanen P, Sorsa T. Pilot study on oral health status as assessed by an active matrix metalloproteinase-8 chairside mouthrinse test in adolescents. *J Periodontol*. 2016;87:36-40.
30. Heikkinen AM, Raivisto T, Kettunen K, et al. Pilot study on the genetic background of an active matrix metalloproteinase-8 test in Finnish adolescents. *J Periodontol*. 2017;88:464-472.
31. Ahead of print. Heikkinen AM, Räisänen IT, Tervahartiala T, Sorsa T. Cross-sectional analysis of risk factors for subclinical periodontitis; active matrix metalloproteinase-8 as a potential indicator in initial periodontitis in adolescents. *J Periodontol*. 2018 Nov 5. doi: 10.1002/JPER.18-0450. [Epub ahead of print]
32. Zhang L, Li X, Yan H, Huang L. Salivary matrix metalloproteinase (MMP)-8 as a biomarker for periodontitis: A PRISMA-compliant systematic review and meta-analysis. *Medicine (Baltimore)*. 2018;97:e9642. doi: 10.1097/MD.00000000000009642

33. Sorsa T, Hernández M, Leppilahti J, Munjal S, Netuschil L, Mäntylä P. Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods. *Oral Dis*. 2010;16:39-45.
34. Sorsa T, Mäntylä P, Tervahartiala T, Pussinen PJ, Gamonal J, Hernandez M. MMP activation in diagnostics of periodontitis and systemic inflammation. *J Clin Periodontol*. 2011;38:817-819.
35. Hernández M, Gamonal J, Tervahartiala T, et al. Associations between matrix metalloproteinase-8 and -14 and myeloperoxidase in gingival crevicular fluid from subjects with progressive chronic periodontitis: A longitudinal study. *J Periodontol*. 2010;81:1644-1652.
36. Mäntylä P, Stenman M, Kinane DF, et al. Gingival crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of periodontitis. *J Periodontal Res*. 2003;38:436-439.
37. Sorsa T, Gieselmann D, Arweiler NB, Hernández M. (2017). A quantitative point-of-care test for periodontal and dental peri-implant diseases. *Nat Rev Dis Primers*. 2017;3:17069. <https://doi.org/10.1038/nrdp.2017.69>
38. Nwhator SO, Ayanbadejo PO, Umezudike KA, et al. Clinical correlates of a lateral-flow immunoassay oral risk indicator. *J Periodontol*. 2014;85:188-194.
39. Lorenz K, Keller T, Noack B, Freitag A, Netuschil L, Hoffmann T. Evaluation of a novel point-of-care test for active matrix metalloproteinase-8: agreement between qualitative and quantitative measurements and relation to periodontal inflammation. *J Periodontal Res*. 2017;52:277-284.
40. Johnson N, Ebersole JL, Kryscio RJ, et al. Rapid assessment of salivary MMP-8 and periodontal disease using lateral flow immunoassay. *Oral Dis*. 2016;22:681-687.
41. Izadi Borujeni S, Mayer M, Eickholz P. Activated matrix metalloproteinase-8 in saliva as diagnostic test for periodontal disease? A case-control study. *Med Microbiol Immunol*. 2015;204:665-672.
42. Hernández-Rios P, Hernández M, Garrido M, et al. Oral fluid matrix metalloproteinase (MMP)-8 as a diagnostic tool in chronic periodontitis. *Metalloproteinases Med*. 2016;3:11-18. <https://doi.org/10.2147/MNM.S89245>
43. Leppilahti JM, Harjunmaa U, Järnstedt J, et al. Diagnosis of newly delivered mothers for periodontitis with a novel oral-rinse aMMP-8 point-of-care test in a rural Malawian population. *Diagnostics (Basel)*. 2018;8:E67. <https://doi.org/10.3390/diagnostics8030067>
44. Räisänen IT, Heikkinen AM, Siren E, et al. Point-of-Care/Chairside aMMP-8 Analytics of Periodontal Diseases' Activity and Episodic Progression. *Diagnostics (Basel)*. 2018;8:E74. <https://doi.org/10.3390/diagnostics8040074>
45. Räisänen IT, Sorsa T, van der Schoor G-J, et al. Active Matrix Metalloproteinase-8 Point-of-Care (PoC) / Chairside Mouthrinse Test vs Bleeding on Probing in Diagnosing Subclinical Periodontitis in Adolescents. *Diagnostics (Basel)*. 2019;9:E34. doi: 10.3390/diagnostics9010034

46. Alassiri S, Parnanen P, Rathnayake N, et al. The Ability of Quantitative, Specific, and Sensitive Point-of-Care/Chair-Side Oral Fluid Immunotests for aMMP-8 to Detect Periodontal and Peri-Implant Diseases. *Dis Markers*. 2018;1306396. doi: 10.1155/2018/1306396
47. World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, 1964 and as revised by the World Medical Assembly in Tokyo, Japan, 1975, in Venice, Italy, 1983, in Hong Kong, 1989, in Somerset West, Republic of South Africa, 1996, in Edinburgh, Scotland, 2000, in Washington, United States, 2002, in Tokyo, Japan, 2004, in Seoul, Korea, 2008. Retrieved from: <https://www.wma.net/wp-content/uploads/2018/07/DoH-Oct2008.pdf>
48. Tuomainen AM, Nyssonen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. *Arterioscler Thromb Vasc Biol*. 2007;27:2722-2728.
49. Ruiz-González A, Esquerda A, Falguera M, et al. Triggering receptor (TREM-1) expressed on myeloid cells predicts bacteremia better than clinical variables in community-acquired pneumonia. *Respirology*. 2011;16:321-325.
50. Zhang J, She D, Feng D, Jia Y, Xie L. Dynamic changes of serum soluble triggering receptor expressed on myeloid cells-1 (TREM-1) reflect sepsis severity and can predict prognosis: a prospective study. *BMC Infect Dis*. 2011;11:53. doi: 10.1186/1471-2334-11-53.

FIGURE LEGEND

Figure 1: A) aMMP-8, B) TREM-1 and C) PGLYRP1 levels according to aMMP-8 Point-of-Care (PoC) test result. The box-and-whiskers plots denote the median, quartiles and extreme values. P values were obtained from Mann Whitney U test.

Figure 2: The relationship between **A)** TREM-1 and aMMP-8, **B)** PGLYRP1 and aMMP-8 and **C)** TREM-1 and PGLYRP1. Spearman's correlation coefficient (r_s) calculated for all three combinations. An exponential (first-order) fit for panels A and B and a linear fit for panel C with 90% confidence interval superimposed on the scatter plot was estimated by Generalized Linear Model.

Figure 3: aMMP-8 Point-of-Care (PoC) test result (“positive”, “negative”) against the number of ≥ 4 mm periodontal pockets (PD) clustered according to TREM-1’s safe zone cut-off point of 75 pg/mL. The box-and-whiskers plots denote the median, quartiles and extreme values.

TABLES

Table 1: Periodontal inflammatory status (bleeding on probing, visual plaque index and root calculus) and oral health habits (toothbrushing) of the adolescents classified by the aMMP-8 PoC test result (positive negative) and TREM-1 (cut-off point 75 pg/mL).

	aMMP-8 PoC - (N = 29)		aMMP-8 PoC + (N = 14)		
	TREM-1 < 75 pg/mL (N = 7)	TREM-1 > 75 pg/mL (N = 22)	TREM-1 < 75 pg/mL (N = 0)	TREM-1 > 75 pg/mL (N = 14)	Kruskal-Wallis Test
	Median (IQR)	Median (IQR)	Median (IQR)	Median (IQR)	<i>P</i> value
BOP (%)	7.10 (1.80- 11.10)	7.60 (3.00- 13.83)	-	12.50 (8.63- 33.05)	0.050
VPI (%)	10.70 (8.30- 14.80)	8.95 (5.68- 16.30)	-	19.05 (9.08- 48.00)	0.117
RC (%)	3.60 (0.00- 5.60)	0.00 (0.00- 4.80)	-	3.65 (0.00- 7.40)	0.296
Toothbrushing	14.00 (7.00- 14.00)	14.00 (7.00- 14.00)	-	10.50 (7.00- 14.00)	0.891
BOP: bleeding on probing; VPI: visual plaque index; RC: root calculus; Toothbrushing: toothbrushing frequency per week.					
aMMP-8 PoC - = aMMP-8 point-of-care test negative; aMMP-8 PoC + = aMMP-8 point-of-care test positive.					